Pregabalin Market size is forecast to reach $890 Million by 2025, growing at a CAGR of 3.67% during the forecast period 2020-2025. Pregabalin, marketed under the brand name Lyrica among others, is a medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, and generalized anxiety disorder. Its use in epilepsy is as an add-on therapy for partial seizures. When used before surgery, it reduces pain but results in greater sedation and visual disturbances. Pregabalin dosage is usually oral. Rising prevalence of diabetes, HIV, cancer, epilepsy, fibromyalgia, and other such disorders among the geriatric population suffering from neuropathic diabetes and major technological advancements in the manufacturing process of pregabalin has resulted in a surge in demand of Pregabalin across the globe. Major healthcare investments by big firms and various product launches by key glove manufacturers like Cipla Limited are some other factors driving the growth of the market. Pregabalin Market Analysis is based on application, end user and geography.
Application - Segment Analysis
Epilepsy held the largest share in the application segment of Pregabalin Market in 2019 and is estimated to grow at a CAGR of 4.03% during the forecast period 2020-2025. It is estimated that about 1.2 percent of U.S. people have active epilepsy. This comes out to about 3.4 million people nationwide — and more than 65 million globally. The demand for proper treatment of epilepsy is driving growth of this segment. Neuropathic Pain segment secured the second largest share in 2019. The prevalence of likely neuropathic pain is 1.9% (S-LANSS) and 3.4% (DN4) and that of possible neuropathic pain is 5.8% (S-LANSS) and 8.1% (DN4). Pregabalin is required for neuropathic pain owing to its relative reliability, easy use, and high tolerance in patients with neuropathic pain. As a successor of gabapentin, pregabalin has been shown to be effective in several models of neuropathic pain, incisional injury, and inflammatory injury. Epilepsy is set to be the fastest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025, owing to increase in its treatment using pregabalin and innovation of better technological treatment using pregabalin.
Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=501796
Report Price: $ 4500 (Single User License)
End User - Segment Analysis
Pharmaceutical companies hold the major share in the end user segment of Pregabalin Market in 2019. The US Food and Drug Administration (FDA) has approved nine generic versions of Pfizer’s nerve pain drug Lyrica (pregabalin), which are the first generics approved for the medication. Increased cases of diseases like epilepsy has resulted in demand for their proper treatment, particularly in the form of pregabalin. New medications have been developed by various pharmaceutical companies and are used to regulate neuropathic pain caused by diabetic peripheral neuropathy. Furthermore, they can also manage symptoms of postherpetic neuralgia, fibromyalgia and neuropathic pain related to spinal cord injury. Pharmaceutical companies’ segment is poised to continue dominating the market with the highest CAGR during the forecast period 2020-2025, owing to increasing investment in manufacturing and research and developments of products of Disposable Medical Examinations Market.
Geography - Segment Analysis
North America dominates the geography segment of Pregabalin Market with a share of more than 38.6% in 2019, followed by Europe. Growing prevalence of diseases like neuropathic diabetes and HIV among the geriatric population has resulted in great demand of pregabalin. A large American study estimated that 47% of patients with diabetes have some peripheral neuropathy. Neuropathy is estimated to be present in 7.5% of patients at the time of diabetes diagnosis. More than half of cases are distal symmetric polyneuropathy. Focal syndromes such as carpal tunnel syndrome (14-30%), radiculopathies/plexopathies, and cranial neuropathies account for the rest. Presence of well-developed healthcare infrastructure and presence of key market players have further fuelled the market growth in this region. Europe held the second largest share in 2019, owing to presence of a well-developed healthcare sector and rapid development of drug industry in recent years.
Asia-Pacific is estimated to grow at the fastest rate at a higher CAGR during the forecast period 2020-2025. This is owing to growing prevalence of diseases like neuropathy and HIV among the geriatric population and entry of new market players in this region.
Drivers – Pregabalin Market
Rapidly growing incidences of diseases like epilepsy and cancer
Epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. Around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. Early 80% of people with epilepsy live in low- and middle-income countries. The number of new cases of cancer (cancer incidence) is 439.2 per 100,000 men and women per year (based on 2011–2015 cases). The number of cancer deaths (cancer mortality) is 163.5 per 100,000 men and women per year (based on 2011–2015 deaths). Prevalence of these diseases are projected to drive the market growth during the forecast period 2020-2025.
Increasing awareness about health
Recent investments have been made for health condition management, and consumers are looking for better treatment options that would help them treat or prevent specific conditions. The second concern is around healthcare management. At the time, consumers were very much in a reactive mode to their approach.
Challenges – Pregabalin Market
Stringent government regulations on manufacture and sales of pregabalin
In recent years, various health concerns have resulted in government coming up with regulatory procedures and taxes on manufacturing and distribution of Pregabalin in the drug market. This is set to drive the market growth during the forecast period 2020-2025.
Talk to one of our sales representative about the full report by providing your details in the link below:
Pregabalin Market Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Pregabalin Market. Pregabalin Market revenue is primarily generated by manufacturing and distribution by the key market players. In 2019, Pregabalin Market share is consolidated by the top players present in the market. Pregabalin Market top 10 companies are Pfizer Inc., Torrent Pharmaceuticals Ltd, Lupin Limited, Zydus Cadila Healthcare Ltd, Cipla Limited, Genesis Remedies, Sanofi, Medley Pharmaceuticals Limited, Genesis Biotec Inc and Biomax among others.
In October 2017, U.S. FDA approved Lyrica® CR (Pregabalin) extended-release tablets CV.
In December 2017, Zydus Pharmaceuticals (USA) Inc received tentative approval from the US health regulator to market pregabalin capsules, used for the management of certain kinds of seizures, nerve pain and fibromyalgia.
In July 2019, InvaGen Pharmaceuticals Inc. (Ciplas wholly owned step-down subsidiary) received final approval for generic version of Pfizer Lyrica.
North America dominated the Pregabalin Market in the year 2019 owing to growing prevalence of diseases like neuropathic diabetes and HIV among the geriatric population, presence of well-developed healthcare infrastructure and presence of key market players. The Pregabalin Market scope for different regions will be provided in the final report.
Rapidly growing incidences of diseases like epilepsy and cancer, as well as increasing awareness about health have helped in significant growth of Pregabalin Market. Innovation and progress of Pregabalin manufacture and increase in research and development of drugs by the key market players of the Pregabalin Industry in upcoming years is estimated to drive the industry growth during the forecast period 2020-2025.
Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Pregabalin Market Research report.
Stringent government regulations on manufacture and sales of pregabalin in many regions and competition from various biosimilars is anticipated to hamper the market growth of the Pregabalin Industry.
Related Reports :
2.Generalized Anxiety Disorder Market
Mr. Venkat Reddy
Email: [email protected]
Contact Sales: +1-614-588-8538 (Ext-101)
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more about our consulting services.